Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown 45 enrolled National Taiwan University Hospital GlaxoSmithKline · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Because of the advantageous activity against VEGF-C and FGF pathways and favorable toxicity profile comparing with sunitinib, the investigators plan this phase II trial of pazopanib in cisplatin-refractory recurrent or metastatic HNSCC.

Timeline

Start: 2011-06
Primary completion: 2013-05
Completion: 2014-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pazopanib	Small molecule	800 mg	Oral

Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications